Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
about
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsIntravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.New drug targets in metastatic melanoma."RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer.Advanced molecular dynamics simulation methods for kinase drug discovery.Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape.Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?Neurological update: gliomas and other primary brain tumours in adults.Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation.Malignant Melanoma.GDA, a web-based tool for Genomics and Drugs integrated analysis.HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosisIs time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
P2860
Q26862544-E89AFA04-DCB3-4F69-88A0-DF5AEBFB3B3DQ35474544-1DFECDF5-697E-4DAF-938C-AA6217A1BF60Q35615183-53B6F230-A3B0-4A05-8C2E-02898CA97A9AQ38136595-0E6D0085-27A7-4CB9-92F7-1C63D392B7D3Q38220879-9E6CE2A3-E28B-4D70-899A-BEB24D925707Q38228386-52632640-CFB5-490A-88E8-BC4392B7B16EQ38656012-2B96A795-EC7D-478D-88B0-B0904E272B4CQ38800768-8F725111-710F-42E9-9B40-19DA158D1488Q38843250-C9C6AA03-CEF8-4B7A-A408-EA3A3ECDE2BEQ39303366-2F3D9AF0-32E3-4BD5-A247-23FB2AFEEE36Q47989137-569EEF45-2D2C-4DA2-9613-30A3BCE90CC4Q49021003-335ED4AB-BFBA-467E-9635-E62DA119EB97Q50052905-F85049B9-2CBD-4E20-A75C-D54C21587B56Q54432652-3876FF44-6090-4D4B-AADA-B5B265BCFED3Q55518834-0AC39386-3430-4C0B-9D5C-7D805DF33A14Q58712149-EFB497C8-A46B-483B-99AF-B56DDB13AB94Q58769992-4E85246A-81BF-40BE-A7AA-6D2C914A89F5
P2860
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@ast
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@nl
type
label
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@ast
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@nl
prefLabel
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@ast
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@nl
P2860
P1476
Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
@en
P2093
Geoffrey T Gibney
Jonathan S Zager
P2860
P304
P356
10.1517/17425255.2013.794220
P407
P577
2013-04-29T00:00:00Z